Skip to main content
Caplight Logo









Autem Therapeutics

Autem Therapeutics

Private
Hanover, New HampshireHealthcare & Life Scienceshttps://www.autemtherapeutics.com/

Last Round

Series A

Extension

Jun 6, 2022

Total Funding Raised

$14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Autem Therapeutics is an oncology and bioelectric technology company developing a non-invasive, non-toxic treatment platform for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

bioelectric medicinenon-invasive cancer treatmenttumor treating fieldsbioelectric oncologyelectromagnetic field therapypersonalized oncologyHepatocellular CarcinomaHCCsolid tumor treatmentmedical devicemedtechGlioblastomaGBMFDA breakthrough designationAI in oncologyclinical stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autem Therapeutics Comparables

Compare Autem Therapeutics with similar companies based on industry and business-model similarity.

Autem Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TheraBionic
86%
EMulate Therapeutics
85%
LifeBridge Innovations, PBC
84%

Autem Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJun 6, 2022

Key People

Founding team and executive leadership

Frederico Perego Costa

Founder & Chief Scientific Officer

Founding Team

Michael Choukas

Co-founder And Chief Executive Officer

Founding Team

Autem Therapeutics Investors

Notable investors and investment history

Autem Therapeutics investors
InvestorRounds
Zentynel Frontier InvestmentsSeries A Extension
Spectra InvestimentosSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 73% MoM.

  • May 15, 2026

    Monthly visitors grew 203% MoM.

Autem Therapeutics Filings

Explore SEC and related filing metadata, where available.

Autem Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Autem Therapeutics's valuation, stock price, and market status.

Is Autem Therapeutics a public or private company?

Autem Therapeutics is a private company.

What is the current stock price of Autem Therapeutics?

Autem Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Autem Therapeutics worth (valuation)?

Valuation information for Autem Therapeutics is not publicly available.

Can I buy Autem Therapeutics stock?

Autem Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Autem Therapeutics's last funding round?

Autem Therapeutics's most recent funding round was Series A Extension on June 6, 2022.

Who are the main investors in Autem Therapeutics?

Key investors in Autem Therapeutics include Zentynel Frontier Investments.

Will Autem Therapeutics IPO soon?

No public IPO plans have been announced for Autem Therapeutics.

How can I track Autem Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Autem Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHanover, New Hampshire
Employee Range16
Year Founded2017
Last FundingJun 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?